JAKaL

• Research type

  Research Study

• Full title

  A phase Ib study of INCB039110, a JAK1 inhibitor, in advanced hepatocellular carcinoma

• IRAS ID

  237279

• Contact name

  R Sharma

• Contact email

  r.sharma@imperial.ac.uk

• Sponsor organisation

  Imperial College London

• Eudract number

  2017-004437-81

• Duration of Study in the UK

  3 years, 9 months, 31 days

• Research summary

  This is a single arm phase Ib study to evaluate the effect of Itacitinib (a JAK1 inhibitor) in -25 patients with advanced HCC where we are trying to assess the safety and tolerability of Itacitinib in patients with advanced hepatocellular carcinoma (HCC). Eligible patients will receive Itacitinib every 400mg QD until disease progression, unacceptable toxicities or withdrawal of consent.
  We would also like to assess the efficacy of Itacitinib by overall response rate (ORR)

• REC name

  Yorkshire & The Humber - Sheffield Research Ethics Committee

• REC reference

  18/YH/0212

• Date of REC Opinion

  13 Aug 2018

• REC opinion

  Further Information Favourable Opinion